Midkine: A multifaceted driver of atherosclerosis

Clin Chim Acta. 2021 Oct:521:251-257. doi: 10.1016/j.cca.2021.07.024. Epub 2021 Jul 28.

Abstract

Atherosclerosis constitutes the pathological basis of life-threatening events, including heart attack and stroke. Midkine is a heparin-binding growth factor and forms a small protein family with pleiotrophin. Under inflammatory or hypoxic conditions, midkine expression is up-regulated. Upon binding to its receptors, midkine can activate multiple signal pathways to regulate cell survival and migration, epithelial-to-mesenchymal transition, and oncogenesis. Circulating midkine levels are significantly increased in patients with essential hypertension, obesity or severe peripheral artery disease. Importantly, midkine exerts a proatherogenic effect by altering multiple pathophysiological processes involving atherogenesis, including macrophage lipid accumulation, vascular inflammation, neointima formation, insulin resistance and macrophage apoptosis. Midkine represents a potential therapeutic target for atherosclerosis-associated diseases. This review described the structure characteristics, expression patterns and signal transduction pathways of midkine with an emphasis on its role in atherosclerosis.

Keywords: Atherosclerosis; Inflammation; Lipid accumulation; Midkine; Neointima formation.

Publication types

  • Review

MeSH terms

  • Atherosclerosis*
  • Cytokines*
  • Fibroblast Growth Factors
  • Humans
  • Macrophages
  • Midkine
  • Signal Transduction

Substances

  • Cytokines
  • Midkine
  • Fibroblast Growth Factors